Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
Press releases
-
New data supporting targeting Trk receptors with ACD856 for treatment of Alzheimer’s disease presented at AAIC 2021
July 29, 2021
-
AlzeCure to present abstract on ACD856 in Alzheimer’s disease at AAIC conference
June 29, 2021
-
New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference
June 11, 2021
Financial reports
-
AlzeCure publishes its interim report for January – March 2021
May 5, 2021
-
AlzeCure Pharma publishes its Annual Report for 2020
April 6, 2021
-
AlzeCure publishes its Year-end report for 2020
February 26, 2021